Food and Drug Administration Animal Rule pathway, according to a corporate update issued by the company on Sept. 22, 2026. The Cambridge, Massachusetts-based biotechnology firm is targeting high-value Priority Review Voucher eligibility as it develops Designable Multi-Antivirals to defend against high-consequence viral threats.
The program follows preclinical breakthroughs announced by Decoy Therapeutics on July 27, 2026, which revealed initial cross-viral activity from the company’s pan-coronavirus fusion inhibitors against wild-type Ebola Zaire and Lassa fever viruses. Following those findings, Decoy initiated a dedicated program to de novo design filovirus fusion inhibitors using its IMP3ACT computational engine, according to company statements.
Preclinical Potency Against Ebola and Marburg Viruses
Decoy Therapeutics reported that a first-generation de novo candidate achieved a low-micromolar half-maximal inhibitory concentration of 1.56 micromolars against wild-type Ebola Zaire virus in cell-based assays. According to the company’s Sept. 22 release, this represents a more than five-fold improvement in potency compared to its pan-coronavirus lead, and a seven-fold improvement over the benchmark antiviral remdesivir.
In addition to its efficacy against Ebola, the candidate demonstrated cross-family activity against the Marburg virus with an IC50 of 1.04 micromolars. Decoy is executing generative design campaigns to establish a single, broad-spectrum pan-filovirus candidate intended for pre- and post-exposure prophylaxis against all human-infecting filoviruses.
Engineering for Extended Prophylactic Utility
Effective prophylaxis against high-consequence pathogens requires sustained drug levels at the site of viral entry. According to Decoy Therapeutics, the IMP3ACT platform is utilized to structurally engineer molecules for extended tissue residence time and long systemic plasma half-lives, with the eventual goal of enabling weekly dosing regimens.
Filoviruses, which include the Ebola and Marburg viruses, cause severe hemorrhagic fevers historically associated with mortality rates ranging between 40% and 90%. The ongoing outbreak of the Bundibugyo virus underscores vulnerabilities in existing therapeutics, which typically target single strains. Decoy’s pan-filovirus approach focuses on the highly conserved helical fusion core shared across filovirus glycoproteins to neutralize viral entry.
Regulatory Pathway and Funding Strategy
Decoy Therapeutics is pursuing the FDA Animal Rule pathway to achieve expedited regulatory approval for its biodefense pipeline.
According to the company, leadership is actively pursuing non-dilutive government grants and public health partnerships to fund preclinical and clinical development. These efforts carry monetization potential through Priority Review Voucher opportunities upon approval, according to the corporate release.
Worth a look